Bridgeworth LLC Takes Position in Merck & Co., Inc. (NYSE:MRK)
Bridgeworth LLC Takes Position in Merck & Co., Inc. (NYSE:MRK)
Bridgeworth LLC bought a new stake in shares of Merck & Co., Inc. (NYSE:MRK – Get Rating) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,518 shares of the company's stock, valued at approximately $207,000.
Bridgeworth LLC在第一季度购买了默克公司(NYSE：MRK-GET Rating)的新股，据该公司最近向美国证券交易委员会(Securities And Exchange Commission)披露的情况。该基金购买了2518股该公司股票，价值约20.7万美元。
A number of other large investors have also recently modified their holdings of MRK. Paulson Wealth Management Inc. boosted its holdings in shares of Merck & Co., Inc. by 1.9% in the 1st quarter. Paulson Wealth Management Inc. now owns 6,144 shares of the company's stock valued at $504,000 after buying an additional 115 shares in the last quarter. Private Management Group Inc. raised its position in shares of Merck & Co., Inc. by 0.4% in the 1st quarter. Private Management Group Inc. now owns 28,832 shares of the company's stock valued at $2,366,000 after purchasing an additional 117 shares during the last quarter. Disciplined Investments LLC raised its position in shares of Merck & Co., Inc. by 24.3% in the 1st quarter. Disciplined Investments LLC now owns 604 shares of the company's stock valued at $50,000 after purchasing an additional 118 shares during the last quarter. Pegasus Asset Management Inc. raised its position in shares of Merck & Co., Inc. by 0.3% in the 1st quarter. Pegasus Asset Management Inc. now owns 34,987 shares of the company's stock valued at $2,871,000 after purchasing an additional 119 shares during the last quarter. Finally, Financial Management Professionals Inc. raised its position in shares of Merck & Co., Inc. by 4.1% in the 1st quarter. Financial Management Professionals Inc. now owns 3,123 shares of the company's stock valued at $256,000 after purchasing an additional 123 shares during the last quarter. Institutional investors own 72.88% of the company's stock.
其他一些大型投资者最近也调整了对MRK的持股。鲍尔森财富管理公司(Paulson Wealth Management Inc.)第一季度增持默克公司(Merck&Co.，Inc.)股票1.9%。保尔森财富管理公司在上个季度又购买了115股保尔森财富管理公司的股票，目前持有6,144股该公司股票，价值50.4万美元。私人管理集团(Private Management Group Inc.)在第一季度将其在默克公司(Merck&Co.，Inc.)股票的持仓增加了0.4%。私人管理集团(Private Management Group Inc.)现在持有该公司28,832股股票，价值2,366,000美元，此前该公司在上个季度又购买了117股。纪律性投资有限责任公司第一季度将其在默克公司股票的持仓量提高了24.3%。纪律投资有限责任公司现在持有604股该公司股票，价值5万美元，在上个季度又购买了118股。飞马资产管理公司(Pegasus Asset Management Inc.)第一季度将其在默克公司(Merck&Co.，Inc.)的股票头寸提高了0.3%。飞马资产管理公司现在持有34,987股该公司股票，价值2,871,000美元，该公司在上个季度又购买了119股。最后，Financial Management Offessionals Inc.在第一季度将其在默克公司股票的持仓提高了4.1%。Financial Management Offessionals Inc.在上个季度购买了123股后，现在持有该公司3,123股股票，价值25.6万美元。机构投资者持有该公司72.88%的股票。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Several equities analysts recently commented on MRK shares. Cowen increased their price objective on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a "market perform" rating in a research report on Monday, June 27th. Daiwa Capital Markets raised shares of Merck & Co., Inc. from a "neutral" rating to a "buy" rating and increased their price objective for the company from $89.00 to $102.00 in a research report on Wednesday, July 6th. Mizuho started coverage on shares of Merck & Co., Inc. in a research report on Friday, June 24th. They issued a "buy" rating and a $100.00 price objective for the company. Atlantic Securities increased their price objective on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, July 13th. Finally, SVB Leerink reissued an "outperform" rating and set a $102.00 price target on shares of Merck & Co., Inc. in a research report on Monday, June 6th. Eight research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $97.44.
几位股票分析师最近对MRK的股票发表了评论。考恩在6月27日周一的一份研究报告中将默克公司股票的目标价从95美元上调至102.00美元，并给予该公司“市场表现”评级。7月6日，大和资本市场在一份研究报告中将默克公司的股票评级从中性上调至买入，并将该公司的目标价从89美元上调至102.00美元。瑞穗在6月24日星期五的一份研究报告中开始对默克公司的股票进行报道。他们对该公司的评级为“买入”，目标价为100.00美元。大西洋证券在7月13日星期三的一份研究报告中将默克公司股票的目标价从105.00美元上调至110.00美元，并给予该公司“增持”评级。最后，SVB Leerink在6月6日周一的一份研究报告中重新发布了对默克公司的评级，并为默克公司的股票设定了102.00美元的目标价。8名研究分析师对该股的评级为持有，9名分析师给予买入评级，2名分析师给予该股强烈买入评级。根据MarketBeat.com的数据，该公司目前的普遍评级为“适度买入”，平均目标价为97.44美元。
Merck & Co., Inc. Price Performance
默克公司性价比
Merck & Co., Inc. (NYSE:MRK – Get Rating) last posted its earnings results on Thursday, July 28th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.69 by $0.18. The firm had revenue of $14.59 billion during the quarter, compared to analyst estimates of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 50.02%. The business's quarterly revenue was up 28.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.31 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 7.31 EPS for the current year.
默克公司(纽约证券交易所代码：MRK-GET评级)最近一次公布收益报告是在7月28日星期四。该公司公布本季度每股收益为1.87美元，比普遍预期的1.69美元高出0.18美元。该公司本季度营收为145.9亿美元，而分析师预期为138.5亿美元。默克公司的净利润率为29.00%，股本回报率为50.02%。该业务的季度收入同比增长28.0%。去年同期，该公司每股收益为1.31美元。股票研究分析师预计，默克公司本财年每股收益将达到7.31美元。
Merck & Co., Inc. Dividend Announcement
默克公司宣布分红
The company also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be issued a dividend of $0.69 per share. This represents a $2.76 annualized dividend and a dividend yield of 3.16%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.'s dividend payout ratio (DPR) is 42.27%.
该公司最近还宣布了季度股息，将于10月7日(星期五)支付。9月15日(星期四)登记在册的股东将获得每股0.69美元的股息。这意味着年化股息为2.76美元，股息收益率为3.16%。本次股息除息日为9月14日星期三。默克公司的股息支付率为42.27%。
Merck & Co., Inc. Company Profile
默克公司公司简介
(Get Rating)
(获取评级)
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
默克公司是一家全球性的医疗保健公司。它通过两个部门运作，制药和动物健康。制药部门提供肿瘤学、医院急性护理、免疫学、神经科学、病毒学、心血管和糖尿病等领域的人类健康药物产品，以及疫苗产品，如预防性儿科、青少年和成人疫苗。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Merck & Co., Inc. (MRK)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
- 免费获取StockNews.com关于默克公司的研究报告(MRK)
- MarketBeat：回顾中的一周8/1-8/5
- 如何利用高贝塔系数股票最大化你的投资利润
- 克罗诺斯集团(Cronos Group Inc.)营收上升，是时候收购了吗？
- Beyond Meat不是没有希望，而且它很便宜
- 苹果为何可能在年底创下历史新高
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Get Rating).
想看看还有哪些对冲基金持有MRK吗？访问HoldingsChannel.com获取默克公司(NYSE：MRK-GET Rating)的最新13F文件和内幕交易信息。
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到默克公司的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对默克公司和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。